Ticker LaunchUplisting · PTIX
Protagenic Therapeutics, Inc.\new
Formerly Atrinsic, Inc.; NEW MOTION, INC.; MPLC, Inc.
Protagenic Therapeutics, Inc.\new (PTIX), already reporting to the SEC, moved up to Nasdaq on Apr 28, 2021 with an offering at $4.15 per share raising $13.2M. Benchmark was lead-left underwriter, joined by Arcadia. Duane Morris advised the company.
Protagenic Therapeutics, Inc. is a development-stage biopharmaceutical company discovering and developing therapies for stress-related neuropsychiatric and mood disorders. It uses synthetic forms of brain signaling peptides, based on Teneurin Carboxy-terminal Associated Peptide research, that dampen overactive stress responses, and is running clinical trials.
- Status
- Uplisting
- Ticker
- PTIX
- Exchange
- Nasdaq
- Listed
- Apr 28, 2021
- Price
- $4.15
- Raised
- $13.2M
- Market cap at IPO price
- $57.2M
- First filed
- Sep 16, 2016
- Company counsel
- Duane Morris
- Sector
- Biotech & pharma
- Country / state
- NY
More on this listing for subscribers
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Sep 16, 2016
- Latest amendment Apr 26, 2021
- Final prospectus (424B4) Apr 28, 2021
- All filings on EDGAR CIK 1022899
Other Biotech & pharma uplistings in 2021
- Evotec SEEVO · Nov 5, 2021 · $435M
- Zivo Bioscience, Inc.ZIVO · Jun 1, 2021 · $13.8M
- Nexentis Technologies Inc.SVFD · May 17, 2021 · $12M
- GT Biopharma, Inc.GTBP · Feb 12, 2021 · $23.6M
- Lexaria Bioscience Corp.LEXX · Jan 14, 2021 · $9.6M
- Zevra Therapeutics, Inc.KMPH · Jan 11, 2021